Heart Failure With Improved Ejection Fraction (HFimpEF): Current Evidence, Clinical Implications, and Future Directions
DOI:
https://doi.org/10.20883/medical.e1676Keywords:
HFimpEF, heart failure, reverse remodelling, guideline-directed medical therapy, left ventricular ejection fraction, prognosisAbstract
Heart failure with improved ejection fraction (HFimpEF) has emerged in recent years as a distinct clinical phenotype within the spectrum of heart failure subtypes. Current evidence supports the hypothesis that HFimpEF represents a state of functional remission rather than a definitive cure, with important clinical implications, particularly for the continuation of guideline-directed medical therapy (GDMT) and for decision-making regarding device therapies. Withdrawal or de-escalation of treatment is associated with high rates of recurrent systolic function deterioration, justifying the indefinite continuation of disease-modifying therapy. A descriptive narrative review of the available literature was performed to summarise current evidence on the definition, epidemiology, pathophysiological mechanisms, left ventricular ejection fraction (LVEF) trajectories, advanced diagnostic tools, and therapeutic considerations in HFimpEF, and to discuss the main knowledge gaps and future research directions. A better understanding of this phenotype will enable more effective risk stratification and progress towards more individualised management of patients with heart failure, with potential benefits for long-term patient outcomes and care.
Downloads
References
Huang L, Zhou P, Zhai M, Feng J, Huang Y, Zhou Q, He C, Li X, Xin A, Zhang Y, Zhang J. Incidence, progression, and outcomes of heart failure with improved ejection fraction: The added value of longitudinally assessed ejection fraction. Int J Cardiol. 2025 Feb 1;420:132759. https://doi.org/ 10.1016/j.ijcard.2024.132759. Epub 2024 Nov 27. PMID: 39608723. DOI: https://doi.org/10.1016/j.ijcard.2024.132759
Weiss A, Flowers A, Eisenberg SD, Wu L, Rodriguez M, Khawaja M, Moras E, Lavie CJ, Fonarow GC, Tang WHW, Bozkurt B, Krittanawong C. A contemporary review on heart failure with improved ejection fraction. NPJ Cardiovasc Health. 2025 Nov 24;2(1):56. https://doi.org/ 10.1038/s44325-025-00093-3. PMID: 41776261; PMCID: PMC12912323. DOI: https://doi.org/10.1038/s44325-025-00093-3
Park H, Lee N, Hwang CH, Cho SG, Choi GH, Cho JY, Yoon HJ, Kim KH, Ahn Y. Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics‑Related Cardiac Dysfunction. JACC CardioOncol. 2024 Sep 17;6(5):699-710. https://doi.org/ 10.1016/j.jaccao.2024.07.018. PMID: 39479323; PMCID: PMC11522502. DOI: https://doi.org/10.1016/j.jaccao.2024.07.018
Pensa AV, Khan SS, Shah RV, Wilcox JE. Heart failure with improved ejection fraction: Beyond diagnosis to trajectory analysis. Prog Cardiovasc Dis. 2024 Jan‑Feb;82:102-112. https://doi.org/ 10.1016/j.pcad.2024.01.014. Epub 2024 Jan 18. PMID: 38244827. DOI: https://doi.org/10.1016/j.pcad.2024.01.014
Kodur N, Tang WHW. Management of Heart Failure With Improved Ejection Fraction: Current Evidence and Controversies. JACC Heart Fail. 2025 Apr;13(4):537-553. https://doi.org/ 10.1016/j.jchf.2025.02.007. PMID: 40204384. DOI: https://doi.org/10.1016/j.jchf.2025.02.007
McElderry B, O'Neill T, Griffin BP, Kalahasti V, Barzilai B, Brateanu A. Factors Associated With Maintenance of an Improved Ejection Fraction: An Echocardiogram‑Based Registry Study. J Am Heart Assoc. 2023 Nov 7;12(21):e031093. https://doi.org/ 10.1161/JAHA.123.031093. Epub 2023 Oct 27. PMID: 37889194; PMCID: PMC10727417. DOI: https://doi.org/10.1161/JAHA.123.031093
Su K, Li M, Wang L, Tian S, Su J, Gu J, Chen S. Clinical characteristics, predictors, and outcomes of heart failure with improved ejection fraction. Int J Cardiol. 2022 Jun 15;357:72-80. https://doi.org/ 10.1016/j.ijcard.2022.03.046. Epub 2022 Mar 23. PMID: 35339576. DOI: https://doi.org/10.1016/j.ijcard.2022.03.046
Schöps LB, Sengeløv M, Modin D, Jørgensen PG, Bruun NE, Fritz‑Hansen T, Gislason G, Wolsk E, Schou M, Biering‑Sørensen T. Parameters associated with improvement of systolic function in patients with heart failure. Heart. 2023 Dec 15;110(1):49-56. https://doi.org/ 10.1136/heartjnl-2023-322371. PMID: 37423743. DOI: https://doi.org/10.1136/heartjnl-2023-322371
Jiang Y, Chen X, Zhang X, Dong S, Liu Y. Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction. BMC Cardiovasc Disord. 2024 Nov 5;24(1):621. https://doi.org/ 10.1186/s12872-024-04288-x. PMID: 39501133; PMCID: PMC11536577. DOI: https://doi.org/10.1186/s12872-024-04288-x
Romero E, Baltodano AF, Rocha P, Sellers‑Porter C, Patel DJ, Soroya S, Bidwell J, Ebong I, Gibson M, Liem DA, Jimenez S, Bang H, Sirish P, Chiamvimonvat N, Lopez JE, Cadeiras M. Clinical, Echocardiographic, and Longitudinal Characteristics Associated With Heart Failure With Improved Ejection Fraction. Am J Cardiol. 2024 Jan 15;211:143-152. https://doi.org/ 10.1016/j.amjcard.2023.10.086. Epub 2023 Nov 2. PMID: 37923155; PMCID: PMC10869234. DOI: https://doi.org/10.1016/j.amjcard.2023.10.086
Huang W, Nurhafizah A, Frederich A, Khairunnisa AR, Kezia C, Fathoni MI, Samban S, Flindy S. Risk and Protective Factors of Poor Clinical Outcomes in Heart Failure with Improved Ejection Fraction Population: A Systematic Review and Meta‑Analysis. Curr Cardiol Rep. 2025 Jan 6;27(1):4. https://doi.org/ 10.1007/s11886-024-02180-w. PMID: 39760806. DOI: https://doi.org/10.1007/s11886-024-02180-w
Stępień K, Nowak K, Kachnic N, Karcińska A, Del Carmen Yika A, Furczyński J, Platschek M, Skorupa M, Wyleciał Z, Zalewski J, Nessler J. Clinical characteristics and long‑term outcomes of patients with heart failure with improved ejection fraction. First Polish experience from LECRA‑HF registry. Adv Med Sci. 2024 Mar;69(1):132-138. https://doi.org/ 10.1016/j.advms.2024.02.009. Epub 2024 Mar 4. PMID: 38447613. DOI: https://doi.org/10.1016/j.advms.2024.02.009
Segev A, Avrahamy B, Fardman A, Matetzky S, Freimark D, Regev O, Kuperstein R, Grupper A. Heart failure with improved ejection fraction: patient characteristics, clinical outcomes and predictors for improvement. Front Cardiovasc Med. 2024 Jul 17;11:1378955. https://doi.org/ 10.3389/fcvm.2024.1378955. PMID: 39087071; PMCID: PMC11288926. DOI: https://doi.org/10.3389/fcvm.2024.1378955
Bossone E, Shea MJ, Nicklas JM, Abrams GD, Das SK. Early spontaneous recovery of left ventricular function in patients with myocarditis. Ital Heart J. 2000 Nov;1(11):758-761. PMID: 11110518.
Amor‑Salamanca A, Guzzo‑Merello G, González‑López E, Domínguez F, Restrepo‑Córdoba A, Cobo‑Marcos M, Gómez‑Bueno M, Segovia‑Cubero J, Alonso‑Pulpón L, García‑Pavía P. Prognostic Impact and Predictors of Ejection Fraction Recovery in Patients With Alcoholic Cardiomyopathy. Rev Esp Cardiol (Engl Ed). 2018 Aug;71(8):612-619. English, Spanish. https://doi.org/ 10.1016/j.rec.2017.11.032. Epub 2018 Apr 9. PMID: 29650446. DOI: https://doi.org/10.1016/j.rec.2017.11.032
Kim KA, Kim SH, Lee KY, Yoon AH, Hwang BH, Choo EH, Kim JJ, Choi IJ, Kim CJ, Lim S, Park MW, Yoo KD, Jeon DS, Ahn Y, Jeong MH, Chang K. Predictors and Long‑Term Clinical Impact of Heart Failure With Improved Ejection Fraction After Acute Myocardial Infarction. J Am Heart Assoc. 2024 Aug 20;13(16):e034920. https://doi.org/ 10.1161/JAHA.124.034920. Epub 2024 Aug 19. PMID: 39158557; PMCID: PMC11963921. DOI: https://doi.org/10.1161/JAHA.124.034920
Imiela AM, Machowski M, Karolak B, Wasilewski O, Landowska M, Żuk‑Łapan A, Piech A, Cader T, Wiśniewska M, Stelmach B, Pruszczyk P. Haemodynamic consequences of acute pulmonary embolism predict risk of CTPA‑related acute kidney injury. ESC Heart Fail. 2025 Dec;12(6):4086-4094. https://doi.org/ 10.1002/ehf2.15392. Epub 2025 Aug 21. PMID: 40836765; PMCID: PMC12719844. DOI: https://doi.org/10.1002/ehf2.15392
Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R, Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W, Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED‑HF): an open‑label, pilot, randomised trial. Lancet. 2019 Jan 5;393(10166):61-73. https://doi.org/ 10.1016/S0140-6736(18)32484-X. Epub 2018 Nov 11. PMID: 30429050; PMCID: PMC6319251. DOI: https://doi.org/10.1016/S0140-6736(18)32484-X
Cheng L, Hammersley D, Ragavan A, Javed S, Mukhopadhyay S, Gregson J, Han J, Khalique Z, Lota A, Pantazis A, Baksi AJ, Carr‑White G, de Marvao A, Ware J, Tayal U, Pennell DJ, Cleland JGF, Prasad SK, Halliday BP. Long‑term follow‑up of the TRED‑HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission. Eur J Heart Fail. 2025 Jan;27(1):113-123. https://doi.org/ 10.1002/ejhf.3475. Epub 2024 Sep 30. PMID: 39349993; PMCID: PMC11798629. DOI: https://doi.org/10.1002/ejhf.3475
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales‑Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia‑Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. https://doi.org/ 10.1093/eurheartj/ehad194. Erratum in: Eur Heart J. 2026 Aug 17:ehag645. https://doi.org/ 10.1093/eurheartj/ehag645. PMID: 37622657.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo‑Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-3639. https://doi.org/ 10.1093/eurheartj/ehad195. Erratum in: Eur Heart J. 2024 Jan 1;45(1):53. https://doi.org/ 10.1093/eurheartj/ehad613. PMID: 37622666.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. https://doi.org/ 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1. Erratum in: J Am Coll Cardiol. 2023 Apr 18;81(15):1551. https://doi.org/ 10.1016/j.jacc.2023.03.002. PMID: 35379503.
Pabon MA, Vardeny O, Vaduganathan M, Desai AS, Claggett BL, Kulac IJ, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Saldarriaga CI, Petrie MC, Merkely B, Borentain M, Mueller K, Viswanathan P, Amarante F, Morris A, McMurray JJV, Solomon SD. Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS‑HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):740-745. https://doi.org/ 10.1001/jamacardio.2025.1101. PMID: 40397470; PMCID: PMC12096322. DOI: https://doi.org/10.1001/jamacardio.2025.1101
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin‑Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer‑Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. https://doi.org/ 10.1056/NEJMoa2206286. Epub 2022 Aug 27. PMID: 36027570. DOI: https://doi.org/10.1056/NEJMoa2206286
Siqueira SRO, Pabon MA, Vaduganathan M, Claggett BL, Lam CSP, Kosiborod MN, de Boer RA, Shah SJ, Fang JC, Desai AS, Jhund PS, Inzucchi SE, Martinez F, Hernandez AF, Petersson M, McMurray JJV, Solomon SD, Vardeny O. Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction. JACC Heart Fail. 2025 Oct;13(10):102585. https://doi.org/ 10.1016/j.jchf.2025.102585. Epub 2025 Aug 19. PMID: 40834567. DOI: https://doi.org/10.1016/j.jchf.2025.102585
Chang DD, Pantlin PG, Benn FA, Ryan Gullatt T, Bernard ML, Elise Hiltbold A, Khatib S, Polin GM, Rogers PA, Velasco‑Gonzalez C, Morin DP. Risk of ventricular arrhythmias following implantable cardioverter‑defibrillator generator change in patients with recovered ejection fraction: Implications for shared decision‑making. J Cardiovasc Electrophysiol. 2023 Jun;34(6):1405-1414. https://doi.org/ 10.1111/jce.15913. Epub 2023 May 5. PMID: 37146210. DOI: https://doi.org/10.1111/jce.15913
Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, Levy WC, Poole JE. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol. 2017 Jul 1;2(7):767-774. https://doi.org/ 10.1001/jamacardio.2017.1413. PMID: 28724134; PMCID: PMC5710619. DOI: https://doi.org/10.1001/jamacardio.2017.1413
Lyon AR, López‑Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler‑Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC Guidelines on cardio‑oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio‑Oncology Society (IC‑OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. https://doi.org/ 10.1093/eurheartj/ehac244. Erratum in: Eur Heart J. 2023 May 7;44(18):1621. https://doi.org/ 10.1093/eurheartj/ehad196. PMID: 36017568.
Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio‑oncology. Mayo Clin Proc. 2014 Sep;89(9):1287-306. https://doi.org/ 10.1016/j.mayocp.2014.05.013. PMID: 25192616; PMCID: PMC4258909. DOI: https://doi.org/10.1016/j.mayocp.2014.05.013
Downloads
Published
Issue
Section
License
Copyright (c) 2026 The copyright to the submitted manuscript is held by the Author, who grants the Journal of Medical Science (JMS) a nonexclusive licence to use, reproduce, and distribute the work, including for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
